Safety, pharmcokinetic and pharmacodynamic study of DS-2969b in healthy subjects: A phase I single-ascending dose study
Latest Information Update: 21 May 2018
At a glance
- Drugs DS 2969 (Primary)
- Indications Clostridium difficile infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 21 May 2018 New trial record
- 10 May 2018 Results published in the Journal of Clinical Pharmacology